Within the wide range of targets it aspires to address, Scholar Rock is currently pinning its hopes on these two growth factor-targeting therapies and betting on their novel approach—targeting latent forms to improve selectivity . . .
- Drug Discovery
- Antibodies
- Cancer
- GEN Edge
- OMICs
- Genetic Disorders
- Musculoskeletal Disorders
- Rare and Neglected Diseases
